HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) reported today that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Lamotrigine Tablets 25 mg, 100 mg, 150 mg, and 200 mg (“Lamotrigine Tablets”). Taro had received tentative approval for this ANDA in March 2008.
